Xaluritamig for relapsed or refractory Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bone or soft-tissue cancer called Ewing sarcoma that has come back or hasn't responded to standard treatment.
- Your cancer must have a specific change in the EWSR1 gene (confirmed by a test).
- You must have had at least one round of chemotherapy that included certain drugs (like doxorubicin and cyclophosphamide).
- You need to be feeling well enough to carry out daily activities (score of 70 or higher on a special scale depending on your age).
- Your major organs (kidneys, liver, lungs, heart, and blood counts) must be working well enough based on blood tests and oxygen levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
This study is testing new drugs for young people (ages 10 and up) with Ewing sarcoma or related tumors that have come back or stopped responding to treatment. The goal is to find promising drugs that may help shrink tumors or slow their growth.
This Phase 2 trial studies naxitamab (a targeted antibody) in children and young adults whose Ewing sarcoma has come back or kept growing despite prior treatment. You may be eligible if the tumor shows a target called GD2 and if your heart, lungs, and past treatment recovery meet safety requirements.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests a new type of immunotherapy that targets a specific genetic change in Ewing sarcoma and a related rare tumor called DSRCT. It may be an option for patients whose cancer has come back, spread, or is very high-risk after standard chemotherapy.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.